Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 1.00 |
| ▸ | ST14 | Q9Y5Y6 | 20/20 | 1.00 |
| ▸ | F2 | P00734 | 16/20 | 1.00 |
| ▸ | PLG | P00747 | 16/20 | 1.00 |
| ▸ | PLAU | P00749 | 16/20 | 1.00 |
| ▸ | TMPRSS6 | Q8IU80 | 4/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12998769 | 0.96 | F10 (1.00) | F10ST14F2PLGPLAU | |
| SCHEMBL19309580 | 0.96 | F10 (1.00) | F10ST14F2PLGPLAU | |
| SCHEMBL8201054 | 0.95 | F10 (1.00) | F10ST14F2PLGPLAU | |
| SCHEMBL14669479 | 0.94 | F10 (0.92) | F10ST14F2PLGPLAU | |
| SCHEMBL8190331 | 0.94 | F10 (1.00) | F10ST14F2PLGPLAU | |
| SCHEMBL8197768 | 0.92 | ST14 (1.00) | F10ST14F2PLGPLAU | |
| SCHEMBL8196664 | 0.92 | ST14 (1.00) | F10ST14F2PLGPLAU | |
| SCHEMBL14669476 | 0.92 | F10 (1.00) | F10ST14F2PLGPLAU | |
| SCHEMBL19309685 | 0.92 | ST14 (1.00) | F10ST14F2PLGPLAU | |
| SCHEMBL8201049 | 0.92 | ST14 (1.00) | F10ST14F2PLGPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013014074-A1 | USE OF TMPRSS2 INHIBITORS AS MEDICAMENTS | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2013-01-31 | — | — | WO | disclosed |
| US-20120270807-A1 | MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA INC. (CA) | 2012-10-25 | — | — | US | disclosed |
| US-20120270807-A1 | MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA INC. (CA) | 2012-10-25 | — | — | US | disclosed |
| US-20120270769-A1 | METHODS OF USING MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA INC. (CA) | 2012-10-25 | — | — | US | disclosed |
| US-20120270769-A1 | METHODS OF USING MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA INC. (CA) | 2012-10-25 | — | — | US | disclosed |
| WO-2011050270-A2 | MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011050276-A1 | METHODS OF USING MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270769-A1 | METHODS OF USING MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | PRSS1, SPINT2, TMPRSS15 | F10 435/4885ST14 212/4885F2 145/4885 |
| US-20120270807-A1 | MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | PRSS1, SPINT2, SERPINB1 | F10 429/4885ST14 178/4885F2 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.